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THE ROCKEFELLER UNIVERSITY
Electron-micrograph (taken by Dr.
John Swanson) of a Group A menin-
gococcus shows the capsule, enclosing
the entin cell, and the cell wall,
which consists of three layers: an outer
membrane, a middle layer (murein)
characteristic of bacterial cells, and a
cytoplasmic membrane.
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In 1978, Professor Emil C. Gotschlich of The Rockefeller
University won an Albert Lasker Award for Clinical Medicine
for his "creative leadership in developing and then demon-
strating the effectiveness of a purified capsular polysaccharide
vaccine in preventing meningococcal diseases:'
What the citation means is that Dr. Gotschlich's research
has helped make it possible to protect millions of people
around the world against a neurologically crippling and some-
times fatal disease: meningitis. With characteristically wry
humor, he once described his achievement as "draft-
induced"; he developed the vaccine in the late 1960s as a
member of a team at the Walter Reed Army Institute of
Research. His original vaccine works against one form of
meningitis called Group C. A second vaccine, which he
helped to test and refine, was developed for another form,
Group A. At present, he is studying a third, more elusive,
form, Group B.
Later this year, Dr. Gotschlich will become head of the
University's world-renowned laboratory of bacteriology and
immunology, which for many years has been under the co-
leadership of Professors Maclyn McCarty and Rebecca C.
Lancefield~ He is heir to a long and brilliant tradition. It is no
exaggeration to say that the laboratory's seminal findings have
profoundly influenced the course of modern biology.
To understand something of the story behind Dr. Gotsch-
lich's achievement-including the tongue-twisting phrase
"purified capsular polysaccharide"-requires a look intO the
complexities of infection, immunization, and research.
Meningitis is an infection of the meninges, the membranes
covering the brain and spinal cord. Its symptoms include rash,
fever, convulsions, and paralysis. The meningococcal bacteria
Neisseria meningitidis are responsible for the major epidemic
forms of the disease. In any human population there may be a
pool of "carriers" whose coughs and sneezes spread the infec-
tion, although they themselves experience only the symptoms
of what seems to be a cold. Because of its mode of transmis-
sion, meningitis has always been a problem wherever large
groups of people, especially young people, are brought
together in close quarters.
Beginning in the 1940s, meningitis was successfully con-
trolled in the developed countries by the use of the sulfa-
nilamide drugs. But in the early 1960s, the infectious organ-
isms began to develop drug resistance, as has happened with
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some other diseases. In the case of the meningococci, how-
ever, the resistance soon. became total and intractable. By the
time Dr. Gotschlich was drafted, in 1966, meningitis was
again a major military problem. It had never ceased to be a
problem in the meningitis belt that cutS across Africa, as well
as in parts of the Middle East, Asia, and Latin America. When
attempts to find another safe and effective antibiotic failed,
researchers re.turned to the idea of immunization.
"READY-MADE SUITS"
In the complex set of responses by which an organism
defends itself against invaders such as microorganisms, the
key fighters are molecules called antibodies. Immunologists
seek to understand, among other things, the mechanisms by
which antibodies recognize and deal with invaders, specifi-
cally the troublemaking foreign proteins and carbohydrates of
the invaders called antigens.
Early in this century, Karl Landsteiner and others found
that antibodies distinguish among various antigens by recog-
nizing differences in their shapes. To engage the antigen, the
antibody must, so to speak, "fit" it. Since Landsteiner's time it
has been verified that the organism does nOt make a new anti-
body to order. Rather, it has an existing inventory of proto-
type antibodies to match a virtually limitless array of antigen
shapes and sizes, including, remarkably, synthetic ones that
don't occur in nature. Landsteiner, who was awarded a Nobel
Prize in 1930 for the classification of blood groups, spent
more than twenty years of his career at The Rockefeller.
Many years later, another Rockefeller immunologist, Pro-
fessor Gerald M. Edelman, who won a Nobel Prize in 1972
for determining the chemical structure of immunoglobulin,
the key molecule of immunity, described the system this
way:
"Antibodies can be likened to ready-made suits. The anti-
gen is a buyer who decides to pick a number of different suits
that fit more or less well, rather than instruct a tailor to make
one suit to fit him to order. To be satisfied, the buyer must
patronize a store with a very large stock of suits in a great vari-
ety of sizes and styles. The immune system is like a store with
an almost unlimited stock, one ready to please any possible
customer. This analogy fails in one important respect: to be
complete it should provide that after each somewhat different
ready-made suit is picked, the manufacturer would proceed
to make thousands of exact copies of it."
Switching metaphors, the antibodies lock in battle with the
antigens. If and when they win, they remain alert and mobi-
lized to recognize the invader and repulse another attack
before it can begin. That is to say, the antigen-antibody
matching process doesn't have to be repeated. The organism
is said to have developed immunity to that infection.
A vaccine mimics the process of natural immunity. It must
contain the disease antigens, to stimulate production of anti-
bodies, but in a quantity or form that does not cause disease.
Vaccines are usually made from killed or weakened infectious
organisms or from a related or benign form. An example of
the latter is the. use of cowpox virus to confer immunity
against smallpox.
SUGAR-COATED PROBLEM
But for some diseases, meningitis among them, this classi-
cal, whole-organism approach doesn't work. To create his
vaccine, Dr. Gotschlich had to find, isolate, and purify the
specific antigen molecules, which, in the case of the meningo-
cocci, are contained in a coating of material that surrounds, or
encapsulates, each bacterium. This coating is composed of
complex carbohydrates called polysaccharides, poly meaning
"many" and saccharide referring to sugars or carbohydrates.
Purified capsular polysaccharide vaccines like Dr. Gotsch-
lich's, and like one developed against pneumonia by Dr. Rob-
ert Austrian of the University of Pennsylvania School of
Medicine, have been hailed as the first of "a new era of bacte-
rial vaccines." In fact, most of the basic research that made
them possible began many years ago at the research hospital
of what was then The Rockefeller Institute for Medical
Research, in work by Oswald T. Avery and Michael Heidel-
berger, among others. (Dr. Heidelberger, now professor
emeritus at New York University, and Dr. Austrian shared
the Lasker Award with Dr. Gotschlich.)
Avery, who died in 1955, is remembered today primarily
for demonstrating that DNA-deoxyribonucleic acid-is the
chemical substance of genes. Avery was a bacteriologist who
did most of his experimental WOlk with a single bacterial spe-
cies, Streptococcus pneumoniae. The virulent forms of pneumo-
cocci, like meningococci, are covered by polysaccharide cap-
sules. It was Avery, Heidelberger, and Professor Walther F.
Goebel, now emeritus, who established in the 1920s that the
polysaccharides of the capsules were the specific antigenic
determinants in the immunological process. That finding
made possible the development of the first vaccine against
bacterial pneumonia. Its effectiveness was demonstrated in an
epidemic in a military population, but because of the success
of new antibiotic therapy, the development of Dr. Austrian's
more broadly applicable vaccine was delayed for many years.
The abandonment of earlier efforts to develop vaccines was
not capricious. As previously mentioned, diseases like pneu-
monia and meningitis are caused by many types of organisms.
No one vaccine has yet been achieved that works against all
forms. Antibiotics appeared to solve that problem. In that
sense, they truly were miracle drugs and, for many diseases,
still are.
Regarding the meningococci, Dr. Gotschlich states: "As
early as the 1930s, polysaccharide material had been isolated
and purified with the idea of a vaccine; but by the time I came
to Walter Reed, those little bottles of white powder didn't
exist anymore. When we first geared up, we really knew noth-
ing about the antigenic structures of the different groups of
bacteria. We had to go back and re-establish the
benchmarks...
The immediate goal of Dr. Gotschlich's team, which
included the late Dr. Malcolm S. Artenstein, who was direc-
tor of bacteriology at Walter Reed, and Dr. Irving Gold-
schneider, now at the University of Connecticut Medical
School, was a vaccine against Group C meningitis.
"If you define an organism as being Group A or B or C,"
Dr. Gotschlich explains, "you do it with an antiserum-a
serum containing antibodies. But unless you know what the
antigen is you don't know what your antiserum actually 'sees'.
So that was our first job-to determine the antigenic struc-
tures and then test them for their ability to induce
antibodies ...
The initial laboratory work-isolation, purification, test-
ing-took two years to complete. A period of careful trials
and refinement followed: in making vaccines, the determina-
tion of dosages and mode of administration is very important.
The vaccine was found to be almost completely effective in
preventing the spread of Group C meningitis. It is now rou-
tinely administered to all American military personnel and
has been used elsewhere to counter sporadic outbreaks.
Group A vaccine, based on the C prototype, has also proved
successful in large-scale field trials in Africa and other areas.
In 1975 it was administered to the entire population of Fin-
land to stop an epidemic. It has also been used in Brazil.
THE SUM OF INTERACTIONS
Emil Gotschlich had planned on a career in medicine like
his grandfather, father, and mother. Born in Bangkok in
1935, where his parents 'were practicing, he came to the
United States in 1950. He did his undergraduate and medical
training at New York University and earned his M.D. in
1959.
"I was in my second year in medical school," he recalls,
"when I discovered research, and I never looked back. There
was a really unusual constellation of people at NYU, Lew
Thomas and AI Stetson especially. They generated a sense of
enormous excitement in the pathology department, where
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students were given the chance to be involved in research
projects in a remarkable way."
Rockefeller Trustee Lewis Thomas, who later became pres-
ident of Memorial Sloan-Kettering Cancer Center where he
is now chancellor, and the late CA. Stetson, Jr., had both
worked early in their careers at The Rockefeller. Stetson did
his postdoctoral training with Dr. McCarty, one of the world's
leading authorities on streptococci and rheumatic fever. In his
own early years at The Rockefeller, Dr. McCarty had been
, the junior member of the team, with Avery and the late Colin
MacLeod, that made the landmark DNA discovery.
Dr. Gotschlich joined Dr. McCarty's laboratory in 1960.
He was interested at that time in the C-reactive protein, a
substance that appears in the blood of patients during the
acute phase of certain infectious diseases and is a useful index
of the progress of infection. It is called C-reactive because it
interacts with a substance known as C-polysaccharide. The
chemistry of C-polysaccharide was then unknown, and its
determination was Dr. Gotschlich's first research accomplish-
ment, in collaboration with Teh-Yung Liu, a member of the
biochemistry laboratory of Nobel Laureate Stanford Moore.
"From that work," he says, "I began to get a feel for how to
deal with polysaccharides and that was, in large part, my prep-
aration for the project at Walter Reed."
For the past several years, back at his Rockefeller lab, Dr.
Gotschlich has been grappling with the "far more baffling"
question of Group B, another epidemic form of meningococ-
cal meningitis.
"You can prepare Group B polysaccharide, you can charac-
terize it, you know exactly what it is, but the problem is, you
inject it into a hundred people and only two of them will form
antibodies. So you know that the Group B polysaccharide can
be antigenic but in most people does not raise their antibody
level.
"The polysaccharide consists of many units of sialic acid, a
sugar which is present in human tissues. If you think of the
polysaccharide molecules as a string of beads, then antibody
usually recognizes each pearl or perhaps a few contiguous
pearls, the antigenic determinant. But we don't know what
the antigenic determinant is in the case of Group B polysac-
charide, because when we break the string of beads into
pieces we find a bunch of beads, but none of them reacts with
the antibody. So the determinant, the pearl, must be in the
way the polysaccharide folds and packs."
Although the meningococci engage most of his bench time,
Dr. Gotschlich also supervises and collaborates in the
research of graduate students and other junior colleagues.
The University's students, all Ph.D. candidates, are working
scientists. Among current projects are studies of the gono-
cocci, the bacteria of gonorrhea, and the streptococci, which
cause both strep infeerions and some endemic (nonepidemic)
forms of meningitis.
Coccal, or round, bacteria are related to one another, but
they differ in important ways. For example, it was discovered
that the gonococci have little hairlike projections on their sur-
face called pili, which are long strands of proteins existing in
many forms and shapes. This finding, reported almost simul-
taneously by Dr. Gotschlich's lab and a group elsewhere, led
to research which showed that the pili are the means by which
the bacteria adhere to the host and cause virulence. The task
now-the search for the pearl-is to go deeper into the
molecular structure of the pili to learn how to interfere with
the progress of gonococcal infection.
Dr. Gotschlich is a clinical scientist eager to help cure dis-
ease. He is also a biologist fascinated with nature's complex
and challenging design.
"I like to think about it structurally. I like to figure out how a
particular structure on the bacterium interacts with particular
structures of the host for a particular effect. That's the fun. And
then one hopes that understanding the sum of these interac-
tions will help explain how disease occurs and, ultimately,
point us in the direction of knowing what to do about ir." 0
